Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772982 | 0.85 | DRD2 (0.60) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11096796 | 0.81 | DRD2 (0.61) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11096050 | 0.80 | DRD2 (0.62) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL9943304 | 0.80 | DRD2 (0.61) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11101398 | 0.80 | DRD2 (0.62) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11095945 | 0.80 | DRD2 (0.62) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL11096032 | 0.79 | DRD2 (0.61) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL11101393 | 0.79 | DRD2 (0.59) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL4187208 | 0.78 | HTR1A (0.65) | HTR1ADRD2HTR2AHTR2CHTR2B | |
| SCHEMBL6627993 | 0.78 | HTR1A (0.67) | HTR1ADRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6821981-B2 | FOR THERAPY OF DISORDERS, SUCH AS ANXIETY, AGGRESSION AND STRESS, AND FOR THE CONTROL OF VARIOUS PHYSIOLOGICAL PHENOMENA, SUCH AS APPETITE, THERMOREGULATION, SLEEP AND SEXUAL BEHAVIOR | WYETH | 2004-11-23 | — | — | US | claimed |
| US-20020193366-A1 | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists | WYETH | 2002-12-19 | — | — | US | claimed |
| WO-2002088132-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE AS 5-HT1AANTAGONISTS | WYETH (US) | 2002-11-07 | — | — | WO | claimed |
| US-6821981-B2 | FOR THERAPY OF DISORDERS, SUCH AS ANXIETY, AGGRESSION AND STRESS, AND FOR THE CONTROL OF VARIOUS PHYSIOLOGICAL PHENOMENA, SUCH AS APPETITE, THERMOREGULATION, SLEEP AND SEXUAL BEHAVIOR | WYETH | 2004-11-23 | — | — | US | disclosed |
| US-20020193366-A1 | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists | WYETH | 2002-12-19 | — | — | US | disclosed |
| WO-2002088132-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE AS 5-HT1AANTAGONISTS | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193366-A1 | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists | HTR2C, HTR1A, HTR3B | HTR1A 2/4885DRD2 22/4885HTR2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.